DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 303 in DePuy Orthopaedics

  1. GlobalData: Top 30 Pharma Companies Spent $112B on R&D in 2013Read the original story w/Photo

    22 hrs ago | Pharmaceutical Processing

    The world's leading 30 pharmaceutical companies spent a combined $112 billion on research and development in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData. The company's report* states that Roche was the R&D spending leader, outlaying nearly $10 billion in 2013.

    Comment?

  2. Travelport appoints Maria Chevalier to enhance corporate and commercial offeringRead the original story w/Photo

    Yesterday | Travelution

    She becomes global vice president of corporate incubation, working alongside group vice president, global accounts & corporate direct sales, Sandra McLeod. She moves from her own consulting firm and was previously global director of travel & meetings services at HP and Johnson & Johnson.

    Comment?

  3. Johnson & Johnson Pulls Out Of Program To Develop Bowel Disease DrugRead the original story

    Yesterday | BioSpace

    Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease. Galapagos said it had received all rights to the GPR84 inhibitor program which included the drug GLPG1205 and said it would continue with a phase 2 study of its own on patients with inflammatory bowel disease ulcerative colitis.

    Comment?

  4. Galapagos loses partner on inflammatory bowel drugRead the original story

    Yesterday | Reuters

    Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease. Galapagos said it had received all rights to the GPR84 inhibitor program which included the drug GLPG1205 and said it would continue with a phase 2 study of its own on patients with inflammatory bowel disease ulcerative colitis.

    Comment?

  5. Can These Top Dividend-Paying Stocks Soar in 2015?Read the original story

    Saturday Dec 13 | The Motley Fool

    Searching for the top dividend paying stocks is easy. Use any screening tool -- The Motley Fool has one here -- and search for dividend yields above a certain threshold.

    Comment?

  6. Test to Predict Alzheimer's: Would You Want to Know?Read the original story w/Photo

    Friday Dec 12 | News Max

    Before Alzheimer's begins to steal the mind, hints of the disorder circulate in the blood, potentially giving people a way to find out if they'll fall victim to the disease years in the future. This year, research teams announced blood tests under development to diagnose Alzheimer's before symptoms arise, including one that predicted the disease's onset with 100 percent accuracy a decade in advance.

    Comment?

  7. DePuy Pinnacle Lawsuits Continue to Add Up in Texas Federal Court...Read the original story w/Photo

    Friday Dec 12 | PRWeb

    ... List reflected 6,947 cases, which represents an increase of 84 new filings since November 1st. (In re: DePuy Orthopaedics Inc. Pinnacle Hip Implant Product Liability Litigation, MDL No. 2244) "Our Firm regularly hears from individuals who were ...

    Comment?

  8. Johnson & Johnson hires former P&G exec Jorge Mesquita as consumer chairmanRead the original story

    Friday Dec 12 | Brand Republic

    Jorge Mesquita, the former P&G group president, will join Johnson & Johnson this month as worldwide chairman of consumer companies. Mesquita will start his new role on 15 December, according to Ad Age.

    Comment?

  9. A Child's Life After Human TraffickingRead the original story w/Photo

    Wednesday Dec 10 | Switched

    Upon arriving at one of our SOS Children's Villages in Nicaragua , I saw 15-year-old David sitting nervously at a table by himself. This was an unusual sight for me.

    Comment?

  10. Johnson & Johnson: Moderate Upside Led By Pharmaceutical DivisionRead the original story w/Photo

    Wednesday Dec 10 | Seeking Alpha

    Johnson & Johnson has launched a number of new pharmaceutical drugs since 2008, including Xarelto, Zytiga, Stelara, and Olysio. These drugs have been quite successful.

    Comment?

  11. APAC Joint Replacement Market to Reach $6.4 Billion by 2020Read the original story

    Wednesday Dec 10 | Digital Post Production

    The Joint Replacement and Joint Reconstruction Market, comprising hip replacement, knee replacement, shoulder replacement and small joint replacement, in the Currently, the growth in the region is driven by chronic medical conditions such as osteoarthritis, rheumatoid arthritis and osteoporosis; technical advancement in implant designs; new joint biomaterials; and robotic and minimally invasive surgeries . Also, the market is pushed by favorable macroeconomic factors, especially in The future growth would be driven by the above-mentioned chronic conditions, younger patients undergoing joint replacement and requiring further revision surgeries during their lifetime.

    Comment?

  12. Putney hires Catherine Conaty as VP of finance and controllerRead the original story

    Wednesday Dec 10 | Bangor Daily News

    Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has hired Catherine Conaty as Vice President of Finance & Controller, reporting to Putney CFO, William McKee. Conaty joins Putney's senior management team to lead the finance department and implement efficient systems and processes to support Putney's commercial growth in 2015 and beyond.

    Comment?

  13. The 50 happiest places to work in AmericaRead the original story w/Photo

    Wednesday Dec 10 | K102

    Business Insider has put out a list of the 50 best companies to work for. Johnson & Johnson tops the list, Broadcom is #2 and Chevron rounds out the top 3.

    Comment?

  14. Why B Corps Should Expand Their Health and Wellness ProgramsRead the original story w/Photo

    Tuesday Dec 9 | Triple Pundit

    Certified B Corporations are companies that have met rigorous, independent standards of social and environmental performance, accountability and transparency. However, like any company, there are always areas of improvement.

    Comment?

  15. Health Care ETFs Take Over Market Leadership RoleRead the original story w/Photo

    Friday Dec 5 | Benzinga

    The market this year has been characterized by leadership in defensive sectors such as utilities that have been boosted by falling interest rates and conservatism in the late stages of this bull market . While the momentum in utilities has continued to prosper, a new sector has taken over the top leadership spot in this year's sector rankings.

    Comment?

  16. Arrowhead Research Names General CounselRead the original story

    Friday Dec 5 | SocalTECH.com

    Pasadena-based Arrowhead Research , which is developing targeted RNAi biopharmaceuticals, said late Thursday that it has named Patrick O'Brien as the company's new General Counsel.

    Comment?

  17. How Much Do Fair-Value Estimates Help The Retail Investor?Read the original story w/Photo

    Thursday Dec 4 | Seeking Alpha

    Fair-value estimates for Johnson & Johnson lead to a range of numbers that seems too wide to form a helpful basis for planning trades. If we use market-price patterns, focus on their most frequently traded value , along with their pattern of concentration around that mode, during the period of observation.

    Comment?

  18. J&J hires Goldman to explore sale of Splenda, say sources-ReutersRead the original story w/Photo

    Wednesday Dec 3 | PE Hub

    Johnson & Johnson , the U.S.-based healthcare company, has hired Goldman Sachs to explore a sale of its artificial sweetener brand Splenda , sources familiar with the matter told Reuters. The process is at an early stage, with prospective buyers currently signing non-disclosure agreements, one of the sources said, speaking on condition of anonymity because the matter is private.

    Comment?

  19. A new debate is needed for biopharmaceuticalsRead the original story w/Photo

    Mar 12, 2014 | EurActiv.com

    The increasing complexity and uncertainty of drug development is hampering the industry's ability to discover new, life-changing innovative medicines, writes Stefan Gijssels. Stefan Gijssels is Vice President for Communication & Public Affairs at Janssen, a Belgian pharmaceutical company, which is part of the Johnson & Johnson group.

    Comment?

  20. Kalorama: Medtronics and Philips Lead Advanced Patient Monitoring Systems MarketRead the original story

    Wednesday Dec 3 | Sys-Con Media

    The market research firm at the global level with more than in sales and twelve percent of the market. Philips is second with less than ten percent.

    Comment?